ICON

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICON (ICLR) reports robust earnings, eyes strategic partnerships for growth

ICON's Q4 2022 earnings reflect strong financial performance and strategic advancements. While facing challenges in pricing and COVID-related headwinds, the company is well-positioned to capitalize on growth opportunities through margin maintenance, strategic partnerships, and M&A focus.

ICON (ICLR) reports stable Q1 earnings, eyes growth amid challenges

ICON's Q1 2023 earnings call highlighted solid financial performance, strategic partnerships, and investments in innovation. While facing challenges in pricing negotiations and biotech funding, the company remains resilient and focused on growth opportunities. Stabilizing backlog burn rates, leveraging innovative tools, and addressing labor market dynamics present avenues for future success.

ICON reports solid Q2 performance and eyes growth opportunities

ICON's Q2 performance reflects growth momentum and strong financial outlook for 2023. Challenges include growth uncertainty and revenue predictability amid customer fluctuations. Opportunities lie in strategic partnerships, margin improvement, and market expansion.

ICON (ICLR) posts robust Q3 results, eyes growth amid challenges

ICON (ICLR) reports strong Q3 earnings, emphasizing revenue growth, strategic partnerships, and operational improvements. The company faces challenges from macroeconomic factors and customer concentration but sees opportunities in RFP growth and R&D budget expansion. With a focus on innovation and adaptability, ICON aims to maintain its strong performance and capitalize on future opportunities.

ICON (ICLR) reports strong Q4 earnings, eyes strategic growth

ICON's strong performance in Q4 and 2023 driven by revenue growth and margin improvement
Challenges include customer concerns over R&D spend and wide revenue guidance range for 2024
Opportunities lie in new partnerships, automation for margin expansion, and capital deployment priorities
Overall, ICON remains competitive, with positive outlook for future growth and development

ICON (ICLR) reports strong Q1 earnings and strategic growth outlook

ICON (ICLR) delivered a strong performance in Q1 2024, with robust financial results, strategic initiatives, and updated guidance reflecting confidence in future prospects.
While facing challenges such as revenue fluctuations and analyst inquiries, the company's strengths in client engagement, operational efficiency, and market positioning provide a solid foundation for growth.
Opportunities in M&A, customer base diversification, and data strategy underscore potential avenues for expansion and innovation, positioning ICON well for continued success in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine's 2024 list of World's Best Companies ICON was ranked as the highest clinical research organisation out of 1,000 companies for the second year in a row, and in its 2025 list of World's Best Companies in Sustainable Growth it was featured at number 57 out of 500 companies. ICON was also an.

ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

ICON Public Limited Company (ICLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

BHP Billiton

Crane Company

ICLR, BHP and CR have been added to the Zacks Rank #5 (Strong Sell) List on December 20, 2024.

New Strong Sell Stocks for December 20th

NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Encourages ICON Public Limited Company (ICLR) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Is Investigating ICON Public Limited Company (ICLR) And Encourages Shareholders to Connect

DUBLIN--(BUSINESS WIRE)--ICON Announces Appointment of Chief Operating Officer.

ICON Announces Appointment of Chief Operating Officer

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Icon Public Limited Company ("ICON" or the "Company") (NASDAQ:ICLR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Icon Public Limited Company. - ICLR

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ICON Public Limited Company (ICLR) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ICON Public Limited Company (ICLR) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

ICON Public Limited Company (ICLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Recent share price weakness is due to temporary headwinds, including client cost-cutting and delays in biotech decision-making, not structural issues in the CRO industry. Long-term prospects remain strong and structural growth drivers are still intact. Short-term headwinds led to attractive valuations, offering a compelling investment opportunity.

ICON: A High Probability Of Success In The Uncertain R&D Process

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Is Investigating ICON Public Limited Company (ICLR) And Encourages Investors to Connect

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Encourages ICON Public Limited Company (ICLR) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Icon Public Limited Company ("ICON" or the "Company") (NASDAQ:ICLR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

ICON Public Limited Company (ICLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ICON Public Limited Company (ICLR) and Encourages Stockholders to Learn More About the Investigation

Bally's

Enphase Energy

BALY, ENPH and ICLR have been added to the Zacks Rank #5 (Strong Sell) List on December 10, 2024.

New Strong Sell Stocks for December 10th

NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Encourages ICON Public Limited Company (ICLR) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / December 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ICON Public Limited Company (ICLR) And Encourages Investors to Reach Out

BENSALEM, Pa. , Dec. 6, 2024 /PRNewswire/ -- Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ICON Public Limited Company (ICLR) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Icon Public Limited Company ("ICON" or the "Company") (NASDAQ:ICLR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company - ICLR

LOS ANGELES , Dec. 5, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of ICON Public Limited Company ("Icon" or the "Company") (NASDAQ: ICLR) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors

DUBLIN--(BUSINESS WIRE)--ICON announces results from a global survey of biopharma professionals on AI and digital innovation adoption within clinical research.

ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQ: ICLR) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Icon investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your.

News for ICON Stock (ICLR)